Tofacitinib as a novel salvage therapy for refractory T-cell large granular lymphocytic leukemia

Leukemia. 2015 Dec;29(12):2427-9. doi: 10.1038/leu.2015.280. Epub 2015 Oct 9.

Authors

B Bilori¹, S Thota², M J Clemente², B Patel², A Jerez³, M Afable Ii², J P Maciejewski²

Affiliations

¹ Yale-Waterbury Internal Medicine Residency Program, Internal Medicine, Waterbury Hospital, Waterbury, CT, USA.
² Department of Translational Hematology and Oncology Research, Cleveland Clinic, Cleveland, OH, USA.
³ Department of Hematology and Medical Oncology, Hospital Universitario Morales Meseguer, Universidad de Murcia, IMIB-Arrixaca, Murcia, Spain.

PMID: 26449659
DOI: 10.1038/leu.2015.280

No abstract available

Publication types

Letter

MeSH terms

Humans
Leukemia, Large Granular Lymphocytic / drug therapy*
Leukemia, Large Granular Lymphocytic / genetics
Mutation
Piperidines / therapeutic use*
Protein Kinase Inhibitors / therapeutic use*
Pyrimidines / therapeutic use*
Pyrroles / therapeutic use*
STAT3 Transcription Factor / genetics
Salvage Therapy*

Substances

Piperidines
Protein Kinase Inhibitors
Pyrimidines
Pyrroles
STAT3 Transcription Factor
STAT3 protein, human
tofacitinib